Addressing manufacturing controls, cell and gene therapies experts and advisers will exchange practical insights and expectations on
for CGTP (cell and gene therapy products) in order to assure that production processes meet technical, regulatory, and cost-efficiency excellence for manufacturing safe products.Read more
While the global gene and cell therapies markets are evolving and the number of clinical trials investigating gene and cell therapies is increases, companies continue facing hurdles with CMC, analytical, process development, and production challenges.
At the 3rd Gene and Cell Therapy: Quality Developments to Commercialization Online Summit on 6-7 October 2021, while addressing manufacturing controls, cell and gene therapies experts and advisers will exchange practical insights and expectations on
for CGTP (cell and gene therapy products) in order to assure:
Cell and gene therapy approvals and fast-track product designations have high support from regulatory bodies, encouraging manufacturers to produce and commercialize these products rapidly.
The leading experts and consultants will share their practical experience and perspectives towards achieving and scaling-up robust cost and quality efficient manufacturing and vector process development, exploring emerging technologies in the field.
Join #VLGeneCell to explore gene and cell therapy development standards and advancements on October 6-7, 2021.
Chief Executives, Vice Presidents, Directors, Heads, Leaders and Managers specializing in:
To request an agenda for this Summit, please complete the details below. We will send you the agenda via email.
Stefano Baila received his PhD in 2007 based upon translational research and development of gene therapies for hemophilia at the Children’s Hospital of Philadelphia. Since that time he has been actively involved in the process development and manufacturing of advanced therapeutic medicinal products through business development and strategic marketing roles at Areta International, a CDMO, and by leading field implementation and commercialization activities for the cell processing unit of Terumo BCT. Stefano also worked as Industrialization Manager at Celyad where he led process development and automation efforts for CAR-T. Now he serves as Director of Operation and BD for Anemocyte
John Taylor is a field-based Process Development Scientist at MilliporeSigma based in Philadelphia, Pennsylvania, USA. John is focused on robust process design, optimization, and scale-up of MilliporeSigma bioprocessing technologies used in biotherapeutics purification. John's current role has allowed him to support cell and gene therapy companies as they navigate through the challenges associated with process development and implementation. Prior to joining MilliporeSigma, he was an Assistant Scientist at Janssen R&D, where he focused on the process development of quick-to-market monoclonal antibodies. John received his M.S. in Biochemical Engineering from Villanova University in 2020 and his B.S. in Biological Engineering from NC State University in 2015.
Request the 3rd Gene and Cell Therapy: Quality Developments to Commercialization Online Summit brochure and find out the latest topics and ideas that will be shared.
Please fill in your e-mail address below and we will process your request in a moment.
I thoroughly enjoyed the conference. It was very well-organized! Kudos to you and the rest of the organizing team. My presentation was well received, and I found the questions and following discussions quite insightful. Thank you again for inviting me. I will be glad to participate in future conferences organized by the Vonlanthen group.
Thank you very much for involving me in this conference, I enjoyed the opportunity.
The Q&A after presentations was very useful, and the presentations were complex and comprehensive. I have enjoyed this experience. Thank you.
Jun 6, 2019
Gene and Cell Therapy: Quality Developments to Commercialization Summit